Eisai's new Alzheimer's drug divides market watchers

Leqembi's price point spurs optimism after Aduhelm, but wide use unclear

The success of Leqembi, developed by Eisai and Biogen, depends on the availability of tests needed for its prescription and other factors. (Photo courtesy of Eisai)

KOHEI YAMADA, Nikkei staff writer

January 23, 2023 01:25 JST

TOKYO -- Analysts are split on the outlook for Japanese drugmaker Eisai's new Alzheimer's treatment, with questions remaining over how many hospitals will have the diagnostic capabilities needed to administer it.

Lecanemab, developed with American partner Biogen, received fast-track approval from the U.S. Food and Drug Administration on Jan. 7. Eisai CEO Haruo Naito estimates that 100,000 American patients will be eligible for the drug in three years.